C4 Therapeutics, Inc. (CCCC) › Shareholders' EquityC4 Therapeutics, Inc. (CCCC) — Shareholders' EquityAnnual figures by fiscal year, from SEC filings.2018: -$79.75M2019: -$111.96M2020: $280.79M2021: $389.61M2022: $289.23M2023: $246.11M2024: $215.99M2025: $256.59M$256.59M2018Shareholders' Equity (USD)2025Fiscal YearShareholders' EquityChange YoY2025$256.59M+18.8%2024$215.99M-12.2%2023$246.11M-14.9%2022$289.23M-25.8%2021$389.61M+38.8%2020$280.79M+350.8%2019-$111.96M-40.4%2018-$79.75M—Other metrics: RevenueCost of RevenueGross ProfitOperating IncomeNet IncomeEPS (Diluted)Total AssetsTotal LiabilitiesCash & EquivalentsOperating Cash FlowCapital ExpendituresShares OutstandingDividends Per Share